Travere Therapeutics Inc. has announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) for FILSPARI® (sparsentan) for the treatment of focal segmental glomerulosclerosis $(FSGS)$, a rare kidney disease. The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of January 13, 2026, for the potential approval. If approved, FILSPARI would become the first FDA-approved treatment specifically for FSGS. This application is supported by positive results from the Phase 3 DUPLEX Study and the Phase 2 DUET Study, which demonstrated the drug's efficacy in reducing proteinuria in both children and adults with FSGS. The FDA has also indicated plans to hold an advisory committee meeting to discuss the application.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.